22.626 articles found

NOVEL COMPOUNDS FOR TREATMENT OF NEURODEGENERATION ASSOCIATED WITH DISEASES, SUCH AS ALZHEIMER'S DISEASE OR DEMENTIA

BLID JAN, GINMAN TOBIAS, GRAVENFORS YLVA, KARLSTROEM SOFIA, KIHLSTROEM JACOB, KOLMODIN KARIN, LINDSTROEM JOHAN, RAHM FREDRIK, SUNDSTROEM MARIE, SWAHN BRITT-MARIE, VIKLUND JENNY, VON BERG STEFAN, VON KIESERITZKY FREDRIK.

· 2010-07-02

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential.

Finberg JP.

Rambam Maimonides Med J · 2010-07-02

DOI: 10.5041/rmmj.10003PMID: 23908775

Copper in diseases and treatments, and copper-based anticancer strategies.

Tisato F, Marzano C, Porchia M, Pellei M, Santini C.

Med Res Rev · 2010-07-01

DOI: 10.1002/med.20174PMID: 19626597

Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.

Johnston TH, van der Meij A, Brotchie JM, Fox SH.

Mov Disord · 2010-07-01

DOI: 10.1002/mds.23069PMID: 20310030

Treatment of benign essential blepharospasm with finasteride: a case report.

Bortolato M, Cannas A, Solla P, Puligheddu M, Muroni A, Marrosu F.

Clin Neuropharmacol · 2010-07-01

DOI: 10.1097/wnf.0b013e3181dca96fPMID: 20386102

Involvement of immune response in the pathogenesis of amyotrophic lateral sclerosis: a therapeutic opportunity?

Calvo A, Moglia C, Balma M, Chiò A.

CNS Neurol Disord Drug Targets · 2010-07-01

DOI: 10.2174/187152710791292657PMID: 20406178

Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).

Stocchi F, Marconi S.

Clin Neuropharmacol · 2010-07-01

DOI: 10.1097/wnf.0b013e3181de8924PMID: 20414107

Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.

Delea TE, Thomas SK, Hagiwara M, Mancione L.

Curr Med Res Opin · 2010-07-01

DOI: 10.1185/03007991003780628PMID: 20429819

Glia as a turning point in the therapeutic strategy of Parkinson's disease.

L' Episcopo F, Tirolo C, Testa N, Caniglia S, Caniglia S, Morale MC, Marchetti B.

CNS Neurol Disord Drug Targets · 2010-07-01

DOI: 10.2174/187152710791292639PMID: 20438439

[Intraduodenal infusion of levodopa].

Valldeoriola F, Cámara A.

Rev Neurol · 2010-07-01

DOI: 10.33588/rn.5101.2010363PMID: 20568067

Long-term effect of unilateral pallidotomy on levodopa-induced dyskinesia.

Kleiner-Fisman G, Lozano A, Moro E, Poon YY, Lang AE.

Mov Disord · 2010-07-01

DOI: 10.1002/mds.23155PMID: 20568091

Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease.

Whitton PS.

Curr Opin Investig Drugs · 2010-07-01

PMID: 20571974